BioWorld

Jan. 15, 2004

View Archived Issues

Adolor's Stock Suffers After Last Entereg Phase III Fails

Despite mediocre results from their fourth Phase III trial, Adolor Corp. and partner GlaxoSmithKline plc expect to seek regulatory approval this year for Entereg in the management of postoperative ileus. (BioWorld Today) Read More

Amgen's CEO Chides Leaders For 'Hiding' From Ethics Fray

Read More

OxiGene Gets $22.3M, Plans Expansion Of CA4P Program

Read More

Enanta Raises $12M To Further Macrolide Respiratory Program

Read More

Other News To Note

Read More